• The Clorox Company recently reported that full-year 2026 net sales fell to US$6,720 million and net income to US$587 million, while issuing fiscal 2027 guidance calling for 13%–14% higher net sales and diluted EPS of US$5.41–US$5.71, helped by its GOJO acquisition.
• At the same time, Clorox’s board approved a small quarterly dividend increase to US$1.25 per share and management highlighted that most business lines are performing at or above expectations, suggesting that productivity initiatives and the early GOJO integration are beginning to support the overall business mix despite recent earnings pressure.
• Now, we’ll explore how Clorox’s upbeat 2027 sales guidance, underpinned by the GOJO acquisition, may influence the company’s existing investment narrative.

Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

Clorox Investment Narrative Recap

To own Clorox, you need to believe its brands, productivity push and digital investments can offset sluggish categories and intense price competition. The latest 2027 guidance leans heavily on the GOJO acquisition, which now looks like the key short term catalyst, while the biggest near term risk remains pressured consumer demand and trade down behavior. The guidance does not remove that risk, but it does put more focus on execution and integration.

Among recent announcements, the new fiscal 2027 outlook is most relevant. Management is calling for 13 percent to 14 percent higher net sales and a 12 percent to 19 percent lift in diluted EPS to US$5.41 to US$5.71, with about 9.5 points of sales growth tied to GOJO. That links directly to the existing catalyst of productivity and ERP benefits, but also raises the stakes if competition, discounting or category softness persist.

But while guidance looks encouraging on paper, investors should still be aware of how rising private label pressure and value seeking behavior could...

Clorox's narrative projects $8.0 billion revenue and $871.3 million earnings by 2029. This requires 6.1% yearly revenue growth and about a $284 million earnings increase from $587.0 million today.

Uncover how Clorox's forecasts yield a $101.71 fair value, a 5% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue of about US$8.1 billion and earnings near US$999 million by 2029, so you can see how views on GOJO driven growth, competition and trade down risk can differ sharply and may shift again after this latest guidance.

Explore 6 other fair value estimates on Clorox - why the stock might be worth 28% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Clorox research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Clorox research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Clorox's overall financial health at a glance.

No Opportunity In Clorox?

Our top stock finds are flying under the radar-for now. Get in early:

• Find 51 companies with promising cash flow potential yet trading below their fair value.
• Outshine the giants: these 17 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 44 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.